Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol. 2023 Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21.
J Clin Oncol. 2023.
PMID: 36809046
Clinical Trial.
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R.
Cortés J, et al. Among authors: deurloo r.
Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.
Future Oncol. 2019.
PMID: 30977385
Item in Clipboard
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, Forstbauer H, Tio J, Grischke EM, Biehl C, Liedtke C, De Haas SL, Deurloo R, Wuerstlein R, Kreipe HH, Gluz O.
Harbeck N, et al. Among authors: deurloo r.
Cancers (Basel). 2021 Sep 29;13(19):4884. doi: 10.3390/cancers13194884.
Cancers (Basel). 2021.
PMID: 34638369
Free PMC article.
Item in Clipboard
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
de Vries EGE, Rüschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, de Groot DJA, Castellano D, Erb G, Naab J, Donica M, Deurloo R, van der Heijden MS, Viale G.
de Vries EGE, et al. Among authors: deurloo r.
Cancer Med. 2023 Jun;12(11):12071-12083. doi: 10.1002/cam4.5893. Epub 2023 Apr 29.
Cancer Med. 2023.
PMID: 37119523
Free PMC article.
Clinical Trial.
Item in Clipboard
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R.
Cameron D, et al. Among authors: deurloo rj.
Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.
Lancet Oncol. 2013.
PMID: 23932548
Clinical Trial.
Item in Clipboard
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
Badve SS, Penault-Llorca F, Reis-Filho JS, Deurloo R, Siziopikou KP, D'Arrigo C, Viale G.
Badve SS, et al. Among authors: deurloo r.
J Natl Cancer Inst. 2022 May 9;114(5):664-675. doi: 10.1093/jnci/djab121.
J Natl Cancer Inst. 2022.
PMID: 34286340
Free PMC article.
Item in Clipboard
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL.
Garcia J, et al. Among authors: deurloo r.
Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. Epub 2020 Mar 26.
Cancer Treat Rev. 2020.
PMID: 32335505
Free article.
Review.
Item in Clipboard
Cite
Cite